Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CPI-444 Capsules, Ciforadenant
CPI-444 · 3 trials · 4 indications
Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.5
Area under the plasma concentration-time curve (AUC) from time zero to infinity
AUC from time zero to the last quantifiable concentration
Percentage of AUC0-∞ that was due to extrapolation from the last quantifiable concentration to infinity
| Arm | Type | Description |
|---|---|---|
| Ciforadenant in combination with daratumumab | EXPERIMENTAL | Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg. |
| Sequence ABC | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed). |
| Sequence BCA | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted). |
| Sequence CAB | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted). |
| Cohort 1 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 2 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 3 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 4 | EXPERIMENTAL | Ciforadenant + atezolizumab |
| Cohort 5 - Closed | EXPERIMENTAL | Ciforadenant |
| Name | Type | Description |
|---|---|---|
| Ciforadenant | DRUG | 100 mg orally twice daily for 28-day cycles |
| daratumumab | DRUG | 16 mg/kg administered intravenously as follows based on 28-day cycles: * Cycles 1 - 2: Days 1, 8, 15, and 22 * Cycles 3 - 6: Days 1 and 15 * Cycles 7 - 24: Day 1 |
| CPI-444 Capsules | DRUG | 100mg Capsule |
| CPI-444 Tablets | DRUG | 100mg Tablets |
| Ciforadenant + atezolizumab | DRUG | Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously. |
Inclusion Criteria: * Relapsed or refractory myeloma. * Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two. * Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting ant...
CPI-444 is an investigational small molecule drug developed by Corvus Pharmaceuticals, Inc. (ticker CRVS). It is being studied in clinical development and has been evaluated in a Phase 1 trial. CPI-444 is also known as CPI-444 Capsules.
CPI-444 targets the adenosine A2a receptor, a receptor protein. By binding to this receptor, CPI-444 is designed to modulate adenosine signaling. The adenosine A2a receptor is part of the adenosine pathway, which can suppress immune responses in the tumor microenvironment.
CPI-444 is being developed by Corvus Pharmaceuticals, Inc., a biopharmaceutical company with the ticker symbol CRVS. Corvus is responsible for the clinical development of CPI-444.
CPI-444 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial.
CPI-444 has been studied in one completed Phase 1 trial, NCT03237988. This trial evaluated the pharmacokinetics of a new tablet formulation of CPI-444 in fed and fasted healthy male and female subjects. It enrolled 24 participants in the United States.
Yes, CPI-444 Capsules is another name for CPI-444. The drug is also referred to as CPI-444 Capsules, reflecting a capsule formulation. Both names refer to the same investigational compound developed by Corvus Pharmaceuticals.